Kantify

Do you know that Kantify is the co-coordinator of the DREAMS consortium who has joined forces to identify promising drugs for 5 neuromuscular disorders? This project is extremely ambitious and is made possible by the unique combination of cutting edge technologies such as AI and induced Pluripotent Stem Cells. Our CEO Ségolène Martin explains below Kantify's and AI's contribution to the project ➡️

[News] AI unveils targets of drugs, starting with Viagra 📣 We are proud to announce today that our AI technology, Sapian, has been leveraged to predict the hidden side of known drugs. As part of an effort to accelerate the repurposing of existing drugs for new indications, Kantify has constituted a unique “Atlas” of how known drugs and molecules interact with all known human proteins. This AI-powered Atlas consists of no less than 78 000 drugs (natural compounds, investigational drugs, and approved drugs) and... 1.4 billion predictions of potential off-targets. In a first White Paper released today, we unveil the Sapian Atlas predictions for a very well known drug, Sildenafil (Viagra). This White Paper authored by Nicolas Maignan, Kantify's COO, presents our novel AI methodology and lists 245 predicted targets for Sildenafil. With this new Atlas, we wish to contribute to a better understanding of the numerous off-targets of drugs, even the ones we (think we) know best, such as Viagra. Find in first comment the link to the full inaugural White Paper and the link to the article published today in the front page of leading economics newspaper L'Echo ! Many thanks to Olivier Gosset 🖊️

[Announcement] We have known for a while now that it was high time to rename our AI platform for drug discovery. We unveil this new name today! "Sapian" is the new name of our Artificial Intelligence platform for drug discovery. The name "Sapian" is derived from "Sapiens," reflecting the platform's emphasis on intelligence and advanced predictive capabilities. "Sapiens," from the Latin "sapere," means "to be wise" or "to know," and is famously associated with "Homo sapiens," the species name for humans, signifying our unique intellectual abilities. By naming our AI platform Sapian, we want to underscore how we combine human-like wisdom and advanced artificial intelligence to revolutionize drug discovery and make treatments available for patients, faster.

On July 22, we celebrate the Fragile X Day with the FRAXA Research Foundation and many other communities worldwide. Fragile X Syndrome (FXS) is the most common inherited single gene cause of autism. At Kantify, we're using Artificial Intelligence to develop innovative treatments for Fragile X. Mathijs van der Lei of University of Antwerp (photo) recently presented at the Gordon Research Conferences how we are jointly using a new assay and AI to measure subtle changes in the behavior of FXS mouse models, making drug testing more efficient. We're testing multiple drugs, targeting different pathways in FXS. We've established an innovative drug screening protocol by combining the multi-electrode array (MEA) for neuronal activity and the live mouse tracker (LMT) for behavior analysis. Preliminary data show alterations in the spontaneous firing and behavior of Fmr1 KO compared to wild-type, offering powerful insights into drug effectiveness. Stay tuned to find out more about our next discoveries! #WorldFragileXDay #FragileX #Research #AI #Biotech #Cure #FRAXA #ResearchUpdates Frank Kooy Caio Hudson Queiroz de Souza Mathijs van der Lei Michael Tranfaglia Nicolas Maignan Nik Subramanian

Nice to see the work of Kantify mentioned in this new article from the Belgian Pharma association pharma.be, where the authors Karen Crabbé and Michèle Melhem explain the potential of Artificial Intelligence for patient-centered innovation in the biopharma sector. in French ➡️ https://lnkd.in/eHyRDGaq in Dutch ➡️ https://lnkd.in/eTBgqXnD

July is #SarcomaAwarenessMonth. Sarcoma is a rare and complex type of cancer that originates in the bones and soft tissues, including muscles, fat, blood vessels, and connective tissues. Due to its rarity, diverse manifestations and often subtle symptoms, sarcoma can be challenging to diagnose. It is still very difficult to treat sarcoma effectively. At Kantify we are working to accelerate the discovery of drugs for sarcomas thanks to new AI approaches. As we already shared on this page, we have very promising results. We will remain committed to make a difference for patients! #raredisease #sarcomaawarenessmonth #AI

It is exciting to see how well Artificial Intelligence can tackle two tricky challenges of drug discovery: - Find new uses for existing drugs (repurposing) - Find therapies for rare diseases ➡️Repurposing and AI were some of the main themes of #rexpo2024 conference on Drug Repurposing, Systems medicine and AI. ➡️ Some of our projects on AI-powered repurposing for rare diseases were presented during the conference. Here is a small recap featuring our cofounder Nik Subramanian and our DREAMS project Coordinator, Dr Xavier Nissan ! https://lnkd.in/epF28gZJ Mónica Pérez Nik Subramanian Xavier Nissan I-Stem AFM-Téléthon Laura Sesma Aguirre Ségolène Martin Yann Guivarch

We are thrilled to announce that Kantify will present its AI platform for target and small molecule discovery during the flagship event "Science for Health", taking place in Brussels in November 2024! Meet you there? ➡️  Full details : https://lnkd.in/eDJQ84GM Rita Prota Marianne Ghyoot Quentin d'Aspremont Myriam Dieleman Sophie Liénart Christophe Coppens

Day 3 of REXPO24, Conference on drug repurposing, is today. Xavier Nissan, Research Director at i-Stem, presented our common Horizon Europe project DREAMS, funded by the European Commission, of which he is the Coordinator. In DREAMS, we combine AI and induced Pluripotent Stem Cells (iPSCs) to discover drugs which are effective on several rare neuromuscular disorders. DREAMS is an ambitious project which relies on initial validations from the long standing collaboration between I-Stem (the French reference for iPSCs) and Kantify (with its novel AI platform for drug discovery). DREAMS gathers a large consortium of excellent research institutes, companies, and the patient organization AFM-Téléthon. NB: do you also notice the resemblance between Xavier Nissan and Kantify's Co-founder Nik Subramanian? Mónica Pérez Laura Sesma Aguirre Hélène Le Borgne Quentin MIAGOUX Yann Guivarch Nicolas Maignan Rubal Ravinder Harald H.H.W. Schmidt Jean-François BRIAND Marc Peschanski Ségolène Martin

Day 2 of REXPO24, Conference on drug repurposing, is underway. Today, Kantify's CTO Nik Subramanian presented some of our novel findings on using Artificial Intelligence to find repurposed drugs which are effective on rare cancers. In his presentation "AI and phenotypic screens lead to the discovery of common treatments for multiple distinct rare diseases with shared commonalities - a use case and what's next", Nik demonstrated how we use Kantify's AI platform to find novel therapeutics targets and drugs. He shared our extremely promising results on some rare cancers with no cures, where in less than 5 months we have successfully predicted and validated novel targets and drugs. Exciting! Harald H.H.W. Schmidt Nik Subramanian REPO4EU Xavier Nissan Maya Jeitany